Article
No evidence that HLA genotype influences the driver mutations that occur in cancer patients.
Cancer immunology, immunotherapy : CII - 1 Apr 2022
Kherreh Noor, Cleary Siobhán, Seoighe Cathal
Abstract excerpt
The major histocompatibility (MHC) molecules are capable of presenting neoantigens resulting from somatic mutations on cell surfaces, potentially directing immune responses against cancer. This led to the hypothesis that cancer driver mutations may occur in gaps in the capacity to present neoantigens that are dependent on MHC genotype. If this is correct, it has important implications for understanding...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.